多基因风险评分可预测心血管疾病患者新发房颤
基于四项TIMI试验中36,662例无房颤史的心血管病患者,分析房颤多基因风险评分(PRS)的预测价值。中位随访2.3年发生1018例新发房颤,PRS每增加1个标准差风险增加40%,高PRS(前20%)较低PRS(后20%)房颤风险增加逾两倍。在CHARGE-AF临床评分和NT-proBNP基础上加入PRS可进一步提升预测区分度。
要点
- 房颤PRS是心血管病患者新发房颤的独立预测因子,每1-SD风险增加40%。
- 高PRS(前20%)者较低PRS(后20%)房颤风险增加逾两倍。
- PRS在CHARGE-AF评分和NT-proBNP之上提供互补预测价值。
核心结论
- 在心血管疾病患者中,房颤PRS是新发房颤的强独立预测因子,与临床风险评分和NT-proBNP联合可提供互补预测价值。
研究设计与样本
- 分析四项TIMI试验中36,662例无既往房颤的受试者,按验证过的房颤PRS五分位分组,临床风险用CHARGE-AF模型计算,随访2.3年。
主要发现
- 低临床风险且低遗传风险者3年房颤发生率为1.3%,高临床风险且高遗传风险者为8.7%。
- 高临床风险、高PRS且NT-proBNP升高亚组的3年房颤风险为16.7%。
- 仅CHARGE-AF评分C-index为0.65,加入NT-proBNP后升至0.67(P<0.001),再加入PRS后升至0.70(P<0.001)。
临床怎么用
- 对心血管病患者可考虑检测房颤PRS,联合CHARGE-AF评分和NT-proBNP识别房颤高危人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Interest in targeted screening programmes for atrial fibrillation (AF) has increased, yet the role of genetics in identifying patients at highest risk of developing AF is unclear. METHODS AND RESULTS: A total of 36,662 subjects without prior AF were analyzed from four TIMI trials. Subjects were divided into quintiles using a validated polygenic risk score (PRS) for AF. Clinical risk for AF was calculated using the CHARGE-AF model. Kaplan-Meier event rates, adjusted hazard ratios (HRs), C-indices, and net reclassification improvement were used to determine if the addition of the PRS improved prediction compared with clinical risk and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Over 2.3 years, 1018 new AF cases developed. AF PRS predicted a significant risk gradient for AF with a 40% increased risk per 1-SD increase in PRS [HR: 1.40 (1.32-1.49); P < 0.001]. Those with high AF PRS (top 20%) were more than two-fold more likely to develop AF [HR 2.45 (1.99-3.03), P < 0.001] compared with low PRS (bottom 20%). Furthermore, PRS provided an additional gradient of risk stratification on top of the CHARGE-AF clinical risk score, ranging from a 3-year incidence of 1.3% in patients with low clinical and genetic risk to 8.7% in patients with high clinical and genetic risk. The subgroup of patients with high clinical risk, high PRS, and elevated NT-proBNP had an AF risk of 16.7% over 3 years. The C-index with the CHARGE-AF clinical risk score alone was 0.65, which improved to 0.67 (P < 0.001) with the addition of NT-proBNP, and increased further to 0.70 (P < 0.001) with the addition of the PRS. CONCLUSION: In patients with cardiovascular conditions, AF PRS is a strong independent predictor of incident AF that provides complementary predictive value when added to a validated clinical risk score and NT-proBNP.
引用
- Marston NA, Garfinkel AC, Kamanu FK, et al. A polygenic risk score predicts atrial fibrillation in cardiovascular disease. Eur Heart J. 2023. PMID: 35980763. doi:10.1093/eurheartj/ehac460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。